Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cellmid, an Australian biotechnology company, has revealed preclinical study results of midkine (MK) for the treatment of acute myocardial infarction (AMI).
Subscribe to our email newsletter
The study results suggested that MK has showed 27% reduction in the area of heart muscle damage as compared to untreated animals undergoing the same procedure.
Dose-ranging studies demonstrated that MK was effective at reducing heart muscle death with doses between 0.1mg/kg and 1.0 mg/kg.
Moreover, MK was safe and well tolerated at doses 16 times greater than the most effective dose of 0.18 mg/kg, with no cardiovascular toxicities observed.